- Home
- AFRM vs BNTX Comparison
AFRM vs BNTX Comparison
Compare AFRM & BNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AFRM | BNTX |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.9B | 22.9B |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | AFRM | BNTX |
|---|---|---|
| Price | $69.99 | $85.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 36 | 21 |
| Target Price | $97.87 | ★ $116.80 |
| AVG Volume (30 Days) | ★ 3.7M | 1.1M |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3586.67 | N/A |
| EPS | ★ 5.53 | N/A |
| Revenue | ★ $4,261,082,000.00 | N/A |
| Revenue This Year | $28.91 | N/A |
| Revenue Next Year | $24.68 | $1.33 |
| P/E Ratio | $13.67 | ★ N/A |
| Revenue Growth | ★ 32.15 | N/A |
| 52 Week Low | $42.10 | $79.81 |
| 52 Week High | $90.44 | $124.00 |
Technical Indicators
Market Signals| Indicator | AFRM | BNTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.91 | 48.75 |
| Support Level | $67.77 | $90.66 |
| Resistance Level | $81.04 | $93.89 |
| Average True Range (ATR) | 3.38 | 2.56 |
| MACD | 0.10 | 0.30 |
| Stochastic Oscillator | 72.01 | 73.74 |
Price Performance
Historical ComparisonAbout AFRM Affirm Holdings Inc.
Founded in 2012, Affirm is a market leader in the buy now, pay later space with around $36 billion in transaction volume in fiscal 2025. Affirm offers both zero-interest financing, which is merchant-subsidized, and interest-bearing loans, which function as personal loans that are approved on a per-transaction basis. Over 70% of Affirm's transaction volume comes from its interest-bearing loans, which also constitute the majority of its revenue. Affirm primarily operates in the United States, which accounted for more than 95% of its revenue in 2025, but it has also expanded to Canada and the United Kingdom.
About BNTX BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.